Larissa J Mooney

Title(s)Professor of Clinical , Psychiatry and Biobehavioral Sciences
SchoolMedicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Greater Southern California Node of the Clinical Trials Network
    NIH UG1DA049435Jun 1, 2019 - Feb 29, 2024
    Role: Co-Principal Investigator
    Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural Function
    NIH R01DA045162Jul 1, 2018 - Apr 30, 2023
    Role: Co-Principal Investigator
    Patient Decision Aid for Medication-Assisted Treatment for Opioid Use Disorder
    NIH R33DA045844Sep 1, 2017 - Aug 31, 2021
    Role: Co-Principal Investigator
    Patient Decision Aid for Medication-Assisted Treatment for Opioid Use Disorder
    NIH R21DA045844Sep 1, 2017 - Aug 31, 2018
    Role: Co-Principal Investigator
    Assessing Functional Outcomes Associated with Reductions in Cannabis Use
    NIH R33DA042280Aug 1, 2016 - Jan 31, 2022
    Role: Co-Principal Investigator
    Assessing Functional Outcomes Associated with Reductions in Cannabis Use
    NIH R21DA042280Aug 1, 2016 - Dec 31, 2018
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Racial and Ethnic Differences in Long-Term Outcomes among Individuals with Opioid Use Disorder at Opioid Treatment Programs. J Racial Ethn Health Disparities. 2024 Dec 28. Zhu Y, Cousins SJ, Clingan SE, Mooney LJ, Saxon AJ, Evans EA, Hser YI. PMID: 39733196.
      View in: PubMed   Mentions:    Fields:    
    2. Impact of COVID-19 on MOUD retention in a sample of rural primary care patients: A secondary analysis of electronic health records. Drug Alcohol Depend Rep. 2024 Sep; 12:100276. Calhoun S, Guo H, Fei Z, Lin C, Clingan SE, Zhu Y, Mooney LJ, Hser YI. PMID: 39286538; PMCID: PMC11403463.
      View in: PubMed   Mentions:
    3. A scoping review of social determinants of health's impact on substance use disorders over the life course. J Subst Use Addict Treat. 2024 Nov; 166:209484. Lin C, Cousins SJ, Zhu Y, Clingan SE, Mooney LJ, Kan E, Wu F, Hser YI. PMID: 39153733; PMCID: PMC11418584.
      View in: PubMed   Mentions:    Fields:    
    4. Brain mGlu5 Is Linked to Cognition and Cigarette Smoking but Does Not Differ From Control in Early Abstinence From Chronic Methamphetamine Use. Int J Neuropsychopharmacol. 2024 Aug 01; 27(8). McClintick MN, Kessler RM, Mandelkern MA, Mahmoudie T, Allen DC, Lachoff H, Pochon JF, Ghahremani DG, Farahi JB, Partiai E, Casillas RA, Mooney LJ, Dean AC, London ED. PMID: 39120945; PMCID: PMC11348008.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Medication-based treatment among rural, primary care patients diagnosed with opioid use disorder and alcohol use disorder. J Subst Use Addict Treat. 2024 Sep; 164:209339. Kan E, Baldwin LM, Mooney LJ, Saxon AJ, Zhu Y, Hser YI. PMID: 38513976; PMCID: PMC11539856.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Medications for Opioid Use Disorder Among Transition Age Youth Compared to Adults 26 or Older in Rural Settings. JAACAP Open. 2024 Dec; 2(4):231-238. Flores JM, Kan E, Mooney LJ, Pham H, Zhu Y, Wolitzky-Taylor K, Hser YI. PMID: 39697397; PMCID: PMC11650659.
      View in: PubMed   Mentions:
    7. Social Determinants of Health and Continuity of Medications for Opioid Use Disorder Among Patients Receiving Treatment in Rural Primary Care Settings. J Addict Med. 2024 May-Jun 01; 18(3):331-334. Pham H, Ober A, Baldwin LM, Mooney LJ, Zhu Y, Fei Z, Hser YI. PMID: 38315721; PMCID: PMC11150102.
      View in: PubMed   Mentions:    Fields:    
    8. Referral of patients from rural primary care clinics to telemedicine vendors for opioid use disorder treatment: A mixed-methods study. J Telemed Telecare. 2024 Jan 22; 1357633X231226261. Lin C, Zhu Y, Mooney LJ, Ober A, Clingan SE, Baldwin LM, Calhoun S, Hser YI. PMID: 38258323; PMCID: PMC11416800.
      View in: PubMed   Mentions:    Fields:    
    9. Co-occurring substance use disorders among patients with opioid use disorder in rural primary care clinics. J Subst Use Addict Treat. 2024 03; 158:209269. Zhu Y, Baldwin LM, Mooney LJ, Saxon AJ, Kan E, Hser YI. PMID: 38097045; PMCID: PMC11522973.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    10. Perceptions of COVID-19 risk during the pandemic: perspectives from people seeking medication for opioid use disorder. Ann Med. 2023 12; 55(1):480-489. Clingan SE, Cousins SJ, Lin C, Nguyen TE, Hser YI, Mooney LJ. PMID: 36692029; PMCID: PMC9879168.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    11. Stakeholder perspectives on a telemedicine referral and coordination model to expand medication treatment for opioid use disorder in rural primary care clinics. J Subst Use Addict Treat. 2024 01; 156:209194. Ober AJ, Dopp AR, Clingan SE, Curtis ME, Lin C, Calhoun S, Larkins S, Black M, Hanano M, Osterhage KP, Baldwin LM, Saxon AJ, Hichborn EG, Marsch LA, Mooney LJ, Hser YI. PMID: 37863356; PMCID: PMC11441624.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Augmenting the efficacy of benzodiazepine taper with telehealth-delivered cognitive behavioral therapy for anxiety disorders in patients using prescription opioids: A pilot randomized controlled trial. Contemp Clin Trials. 2023 10; 133:107334. Wolitzky-Taylor K, Mooney LJ, Otto MW, Metts A, Parsons EM, Hanano M, Ram R. PMID: 37730196; PMCID: PMC10960249.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Identifying patients with opioid use disorder using International Classification of Diseases (ICD) codes: Challenges and opportunities. Addiction. 2024 01; 119(1):160-168. Osterhage KP, Hser YI, Mooney LJ, Sherman S, Saxon AJ, Ledgerwood M, Holtzer CC, Gehring MA, Clingan SE, Curtis ME, Baldwin LM. PMID: 37715369; PMCID: PMC10846664.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Telemedicine-delivered treatment for substance use disorder: A scoping review. J Telemed Telecare. 2023 Aug 03; 1357633X231190945. Pham H, Lin C, Zhu Y, Clingan SE, Lin LA, Mooney LJ, Murphy SM, Campbell CI, Liu Y, Hser YI. PMID: 37537907; PMCID: PMC11444076.
      View in: PubMed   Mentions: 6     Fields:    
    15. Medication treatment for opioid use disorder among rural primary care patients. J Rural Health. 2024 01; 40(1):195-199. Hser YI, Zhu Y, Baldwin LM, Mooney LJ, Saxon AJ. PMID: 37495899; PMCID: PMC10811271.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Care coordination between rural primary care and telemedicine to expand medication treatment for opioid use disorder: Results from a single-arm, multisite feasibility study. J Rural Health. 2023 09; 39(4):780-788. Hser YI, Mooney LJ, Baldwin LM, Ober A, Marsch LA, Sherman S, Matthews A, Clingan S, Fei Z, Zhu Y, Dopp A, Curtis ME, Osterhage KP, Hichborn EG, Lin C, Black M, Calhoun S, Holtzer CC, Nesin N, Bouchard D, Ledgerwood M, Gehring MA, Liu Y, Ha NA, Murphy SM, Hanano M, Saxon AJ. PMID: 37074350; PMCID: PMC10718290.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    17. Alcohol Use Among Treatment-Seeking Individuals With Opioid Use Disorder. J Stud Alcohol Drugs. 2023 07; 84(4):579-584. Baskerville WA, Grodin EN, Lin J, Miotto K, Mooney LJ, Ray LA. PMID: 37096768; PMCID: PMC10488310.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Psychosis among individuals with methamphetamine use disorder is associated with elevated rates of hospitalizations and emergency department visits across an academic health care system. J Subst Use Addict Treat. 2023 08; 151:209033. Zito MF, Fei Z, Zhu Y, Clingan SE, Marder SR, Mooney LJ. PMID: 37011880.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United States. Drug Alcohol Depend. 2023 01 01; 242:109711. Lin C, Pham H, Zhu Y, Clingan SE, Lin LA, Murphy SM, Campbell CI, Sorrell TR, Liu Y, Mooney LJ, Hser YI. PMID: 36462230; PMCID: PMC9683518.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    20. Medical conditions of primary care patients with documented cannabis use and cannabis use disorder in electronic health records: a case control study from an academic health system in a medical marijuana state. Subst Abuse Treat Prev Policy. 2022 05 08; 17(1):36. Padwa H, Huang D, Mooney L, Grella CE, Urada D, Bell DS, Bass B, Boustead AE. PMID: 35527269; PMCID: PMC9080201.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    21. The opioid use disorder core outcomes set (OUD-COS) for treatment research: findings from a Delphi consensus study. Addiction. 2022 09; 117(9):2438-2447. Karnik NS, Marsden J, McCluskey C, Boley RA, Bradley KA, Campbell CI, Curtis ME, Fiellin D, Ghitza U, Hefner K, Hser YI, McHugh RK, McPherson SM, Mooney LJ, Moran LM, Murphy SM, Schwartz RP, Shmueli-Blumberg D, Shulman M, Stephens KA, Watkins KE, Weiss RD, Wu LT. PMID: 35293064; PMCID: PMC9543602.
      View in: PubMed   Mentions: 6     Fields:    
    22. Medication Treatment for Opioid Use Disorder Reduces Suicide Risk. Am J Psychiatry. 2022 04; 179(4):262-263. Mooney LJ. PMID: 35360917.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    23. The Management of Substance Use Disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2022 05; 175(5):720-731. Perry C, Liberto J, Milliken C, Burden J, Hagedorn H, Atkinson T, McKay JR, Mooney L, Sall J, Sasson C, Saxon A, Spevak C, Gordon AJ, VA/DoD Guideline Development Group. PMID: 35313113.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    24. Social Determinants of Mortality of COVID-19 and Opioid Overdose in American Rural and Urban Counties. J Addict Med. 2022 Jan-Feb 01; 16(1):e52-e55. Zhu Y, Fei Z, Mooney LJ, Huang K, Hser YI. PMID: 35120068; PMCID: PMC8815643.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsPHPublic Health
    25. Association Between Benzodiazepine and Opioid Prescription and Mortality Among Patients in a Large Healthcare System. J Addict Med. 2022 Jan-Feb 01; 16(1):65-71. Mooney LJ, Zhu Y, Yoo CK, Wolitzky-Taylor K, Hser YI. PMID: 35120065; PMCID: PMC8817063.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    26. Craving among individuals with stimulant use disorder in residential social model-based treatment - Can exercise help? Drug Alcohol Depend. 2022 02 01; 231:109247. Salem BA, Gonzales-Castaneda R, Ang A, Rawson RA, Dickerson D, Chudzynski J, Penate J, Dolezal B, Cooper CB, Mooney LJ. PMID: 34999268; PMCID: PMC10978100.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    27. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. Drug Alcohol Depend. 2021 11 01; 228:108996. Zhu Y, Mooney LJ, Yoo C, Evans EA, Kelleghan A, Saxon AJ, Curtis ME, Hser YI. PMID: 34555691; PMCID: PMC8674982.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    28. Disparities in digital access among American rural and urban households and implications for telemedicine-based services. J Rural Health. 2022 06; 38(3):512-518. Curtis ME, Clingan SE, Guo H, Zhu Y, Mooney LJ, Hser YI. PMID: 34355427; PMCID: PMC9827725.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    29. Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine. Adv Drug Alcohol Res. 2021; 1. Cameron CM, Nieto S, Bosler L, Wong M, Bishop I, Mooney L, Cahill CM. PMID: 35265942; PMCID: PMC8903193.
      View in: PubMed   Mentions: 3  
    30. The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives. J Subst Abuse Treat. 2022 02; 133:108544. Lin C, Clingan SE, Cousins SJ, Valdez J, Mooney LJ, Hser YI. PMID: 34183213; PMCID: PMC8702565.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsPHPublic Health
    31. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. Addiction. 2022 01; 117(1):151-161. Hser YI, Zhu Y, Fei Z, Mooney LJ, Evans EA, Kelleghan A, Matthews A, Yoo C, Saxon AJ. PMID: 34105213; PMCID: PMC8710136.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    32. Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial. Addict Sci Clin Pract. 2021 04 20; 16(1):24. Hser YI, Ober AJ, Dopp AR, Lin C, Osterhage KP, Clingan SE, Mooney LJ, Curtis ME, Marsch LA, McLeman B, Hichborn E, Lester LS, Baldwin LM, Liu Y, Jacobs P, Saxon AJ. PMID: 33879260; PMCID: PMC8056373.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    33. Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus study. Trials. 2021 Jan 28; 22(1):102. Karnik NS, Campbell CI, Curtis ME, Fiellin DA, Ghitza U, Hefner K, Hser YI, McHugh RK, Murphy SM, McPherson SM, Moran L, Mooney LJ, Wu LT, Shmueli-Blumberg D, Shulman M, Schwartz RP, Stephens KA, Watkins KE, Marsden J. PMID: 33509278; PMCID: PMC7841754.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    34. Effect of screening, brief intervention and referral to treatment for unhealthy alcohol and other drug use in mental health treatment settings: a randomized controlled trial. Addiction. 2021 01; 116(1):159-169. Karno MP, Rawson R, Rogers B, Spear S, Grella C, Mooney LJ, Saitz R, Kagan B, Glasner S. PMID: 32415721; PMCID: PMC7666646.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic Health
    35. Integrating Telemedicine for Medication Treatment for Opioid Use Disorder in Rural Primary Care: Beyond the COVID Pandemic. J Rural Health. 2021 01; 37(1):246-248. Hser YI, Mooney LJ. PMID: 32579751; PMCID: PMC7361555.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsPHPublic Health
    36. The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2020 03; 112S:4-11. Marsch LA, Campbell A, Campbell C, Chen CH, Ertin E, Ghitza U, Lambert-Harris C, Hassanpour S, Holtyn AF, Hser YI, Jacobs P, Klausner JD, Lemley S, Kotz D, Meier A, McLeman B, McNeely J, Mishra V, Mooney L, Nunes E, Stafylis C, Stanger C, Saunders E, Subramaniam G, Young S. PMID: 32220409; PMCID: PMC7134325.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    37. Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD): Rationale, methodology, and preliminary results. J Subst Abuse Treat. 2020 01; 108:115-122. Mooney LJ, Valdez J, Cousins SJ, Yoo C, Zhu Y, Hser YI. PMID: 31668516; PMCID: PMC7397558.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    38. Medication Adherence Monitoring Using Smartphone Video Dosing in an Open-label Pilot Study of Monthly Naltrexone Plus Once-daily Bupropion for Methamphetamine Use Disorder: Feasibility and Acceptability. J Addict Med. 2019 Sep/Oct; 13(5):372-378. Walker R, Hillhouse M, Perrochet B, Sparenborg S, Mooney L, Ling W. PMID: 30724759; PMCID: PMC6675664.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    39. Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks, Offering a Public Health Perspective-A Commentary on Camenga et al. J Stud Alcohol Drugs. 2019 07; 80(4):403-405. Gonzales-Castaneda R, Mooney LJ, Rawson RA. PMID: 31495375; PMCID: PMC6739646.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    40. Relationships between marijuana use, severity of marijuana-related problems, and health-related quality of life. Psychiatry Res. 2019 09; 279:237-243. Liao JY, Mooney LJ, Zhu Y, Valdez J, Yoo C, Hser YI. PMID: 30876731; PMCID: PMC6713587.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    41. Escalating Opioid Dose Is Associated With Mortality: A Comparison of Patients With and Without Opioid Use Disorder. J Addict Med. 2019 Jan/Feb; 13(1):41-46. Hser YI, Saxon AJ, Mooney LJ, Miotto K, Zhu Y, Yoo CK, Liang D, Huang D, Bell DS. PMID: 30418260; PMCID: PMC6349485.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    42. Reduction in Cannabis Use and Functional Status in Physical Health, Mental Health, and Cognition. J Neuroimmune Pharmacol. 2018 12; 13(4):479-487. Mooney LJ, Zhu Y, Yoo C, Valdez J, Moino K, Liao JY, Hser YI. PMID: 30284156; PMCID: PMC6293461.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    43. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol. 2018 12; 13(4):488-497. Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, Hser YI. PMID: 30094695; PMCID: PMC6224303.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    44. Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017 10; 81:53-58. Hser YI, Mooney LJ, Huang D, Zhu Y, Tomko RL, McClure E, Chou CP, Gray KM. PMID: 28847455; PMCID: PMC5607644.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    45. High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System. J Addict Med. 2017 Jul/Aug; 11(4):315-319. Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Zhu Y, Liang D, Huang D. PMID: 28426439; PMCID: PMC5930020.
      View in: PubMed   Mentions: 65     Fields:    
    46. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257. Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, Levin FR. PMID: 28623823; PMCID: PMC5535813.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimals
    47. Chronic pain among patients with opioid use disorder: Results from electronic health records data. J Subst Abuse Treat. 2017 06; 77:26-30. Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. PMID: 28476267; PMCID: PMC5424616.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    48. Mindfulness Based Relapse Prevention for Stimulant Dependent Adults: A Pilot Randomized Clinical Trial. Mindfulness (N Y). 2017 Feb; 8(1):126-135. Glasner-Edwards S, Mooney LJ, Ang A, Garneau HC, Hartwell E, Brecht ML, Rawson RA. PMID: 28191264; PMCID: PMC5300086.
      View in: PubMed   Mentions: 23  
    49. Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. J Addict Med. 2016 Jul-Aug; 10(4):236-43. Mooney LJ, Hillhouse MP, Thomas C, Ang A, Sharma G, Terry G, Chang L, Walker R, Trivedi M, Croteau D, Sparenborg S, Ling W. PMID: 27379819; PMCID: PMC4969133.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    50. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction. 2016 08; 111(8):1416-27. Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, Matthews AG, Hasson A, Annon J, Sparenborg S, Liu DS, McCormack J, Church S, Swafford W, Drexler K, Schuman C, Ross S, Wiest K, Korthuis PT, Lawson W, Brigham GS, Knox PC, Dawes M, Rotrosen J. PMID: 26948856; PMCID: PMC4940267.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    51. Effect of Exercise Training on Striatal Dopamine D2/D3 Receptors in Methamphetamine Users during Behavioral Treatment. Neuropsychopharmacology. 2016 May; 41(6):1629-36. Robertson CL, Ishibashi K, Chudzynski J, Mooney LJ, Rawson RA, Dolezal BA, Cooper CB, Brown AK, Mandelkern MA, London ED. PMID: 26503310; PMCID: PMC4832026.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    52. Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories. Am J Addict. 2015 Oct; 24(7):667-75. Jacobs P, Ang A, Hillhouse MP, Saxon AJ, Nielsen S, Wakim PG, Mai BE, Mooney LJ, S Potter J, Blaine JD. PMID: 26400835; PMCID: PMC5322942.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    53. Impact of an exercise intervention on methamphetamine use outcomes post-residential treatment care. Drug Alcohol Depend. 2015 Nov 01; 156:21-28. Rawson RA, Chudzynski J, Mooney L, Gonzales R, Ang A, Dickerson D, Penate J, Salem BA, Dolezal B, Cooper CB. PMID: 26371404; PMCID: PMC4633370.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansPHPublic Health
    54. The Impact of Exercise On Depression and Anxiety Symptoms Among Abstinent Methamphetamine-Dependent Individuals in A Residential Treatment Setting. J Subst Abuse Treat. 2015 Oct; 57:36-40. Rawson RA, Chudzynski J, Gonzales R, Mooney L, Dickerson D, Ang A, Dolezal B, Cooper CB. PMID: 25934458; PMCID: PMC4560957.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    55. Predictors of depression outcomes among abstinent methamphetamine-dependent individuals exposed to an exercise intervention. Am J Addict. 2015 Apr; 24(3):246-251. Haglund M, Ang A, Mooney L, Gonzales R, Chudzynski J, Cooper CB, Dolezal BA, Gitlin M, Rawson RA. PMID: 25907813.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    56. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014 Dec; 28(12):1115-26. Glasner-Edwards S, Mooney LJ. PMID: 25373627; PMCID: PMC5027896.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    57. Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials. 2014 Nov; 39(2):211-23. McClure EA, Sonne SC, Winhusen T, Carroll KM, Ghitza UE, McRae-Clark AL, Matthews AG, Sharma G, Van Veldhuisen P, Vandrey RG, Levin FR, Weiss RD, Lindblad R, Allen C, Mooney LJ, Haynes L, Brigham GS, Sparenborg S, Hasson AL, Gray KM. PMID: 25179587; PMCID: PMC4252394.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    58. Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction. 2014 Sep; 109(9):1489-500. Ling W, Chang L, Hillhouse M, Ang A, Striebel J, Jenkins J, Hernandez J, Olaer M, Mooney L, Reed S, Fukaya E, Kogachi S, Alicata D, Holmes N, Esagoff A. PMID: 24825486; PMCID: PMC4127124.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    59. Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users. J Subst Abuse Treat. 2015 Jan; 48(1):70-6. Nielsen S, Hillhouse M, Mooney L, Ang A, Ling W. PMID: 25065489; PMCID: PMC4250309.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    60. Exercise training improves heart rate variability after methamphetamine dependency. Med Sci Sports Exerc. 2014 Jun; 46(6):1057-66. Dolezal BA, Chudzynski J, Dickerson D, Mooney L, Rawson RA, Garfinkel A, Cooper CB. PMID: 24162556; PMCID: PMC3999306.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    61. Exercise for methamphetamine dependence: rationale, design, and methodology. Contemp Clin Trials. 2014 Jan; 37(1):139-47. Mooney LJ, Cooper C, London ED, Chudzynski J, Dolezal B, Dickerson D, Brecht ML, Peñate J, Rawson RA. PMID: 24291456; PMCID: PMC4431553.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    62. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. Am J Addict. 2014 Jul-Aug; 23(4):343-8. Nielsen S, Hillhouse M, Weiss RD, Mooney L, Sharpe Potter J, Lee J, Gourevitch MN, Ling W. PMID: 24112096; PMCID: PMC4151625.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    63. Does Posttraumatic Stress Disorder (PTSD) Affect Post-Treatment Methamphetamine Use? J Dual Diagn. 2013 Apr 01; 9(2):123-128. Glasner-Edwards S, Mooney LJ, Ang A, Hillhouse M, Rawson R. PMID: 24065875; PMCID: PMC3779468.
      View in: PubMed   Mentions: 5     Fields:    
    64. Eight weeks of exercise training improves fitness measures in methamphetamine-dependent individuals in residential treatment. J Addict Med. 2013 Mar-Apr; 7(2):122-8. Dolezal BA, Chudzynski J, Storer TW, Abrazado M, Penate J, Mooney L, Dickerson D, Rawson RA, Cooper CB. PMID: 23552821; PMCID: PMC3617407.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    65. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology. Contemp Clin Trials. 2013 Mar; 34(2):196-204. Mooney LJ, Nielsen S, Saxon A, Hillhouse M, Thomas C, Hasson A, Stablein D, McCormack J, Lindblad R, Ling W. PMID: 23159524; PMCID: PMC3760415.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    66. Advances in opioid antagonist treatment for opioid addiction. Psychiatr Clin North Am. 2012 Jun; 35(2):297-308. Ling W, Mooney L, Wu LT. PMID: 22640757; PMCID: PMC4178977.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    67. Comparing buprenorphine induction experience with heroin and prescription opioid users. J Subst Abuse Treat. 2012 Oct; 43(3):285-90. Nielsen S, Hillhouse M, Mooney L, Fahey J, Ling W. PMID: 22301084; PMCID: PMC3350757.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    68. Selective review and commentary on emerging pharmacotherapies for opioid addiction. Subst Abuse Rehabil. 2011; 2:181-8. Ling W, Mooney L, Zhao M, Nielsen S, Torrington M, Miotto K. PMID: 24474855; PMCID: PMC3846315.
      View in: PubMed   Mentions: 4  
    69. Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev. 2011 May; 30(3):300-5. Ling W, Mooney L, Hillhouse M. PMID: 21545561; PMCID: PMC4170948.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    70. Bulimia nervosa among methamphetamine dependent adults: association with outcomes three years after treatment. Eat Disord. 2011 May-Jun; 19(3):259-69. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R. PMID: 21516550; PMCID: PMC3159413.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    71. Prescription and over-the-counter drug treatment admissions to the California public treatment system. J Subst Abuse Treat. 2011 Apr; 40(3):224-9. Gonzales R, Brecht ML, Mooney L, Rawson RA. PMID: 21193282; PMCID: PMC4018412.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    72. Anxiety disorders among methamphetamine dependent adults: association with post-treatment functioning. Am J Addict. 2010 Sep-Oct; 19(5):385-90. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, Methamphetamine Treatment Project Corporate Authors. PMID: 20716300; PMCID: PMC3159418.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    73. The relationship between methamphetamine use and increased dental disease. J Am Dent Assoc. 2010 Mar; 141(3):307-18. Shetty V, Mooney LJ, Zigler CM, Belin TR, Murphy D, Rawson R. PMID: 20194387; PMCID: PMC2947197.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    74. The methamphetamine problem in the United States. Annu Rev Public Health. 2010; 31:385-98. Gonzales R, Mooney L, Rawson RA. PMID: 20070191; PMCID: PMC4440680.
      View in: PubMed   Mentions: 137     Fields:    Translation:Humans
    75. Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev. 2010 Jan; 29(1):12-20. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RA, Methamphetamine Treatment Project Corporate Authors. PMID: 20078677; PMCID: PMC3772133.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    76. Health conditions in methamphetamine-dependent adults 3 years after treatment. J Addict Med. 2009 Sep; 3(3):155-63. Mooney LJ, Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Hunter J, Haning W, Colescott P, Ling W, Rawson R. PMID: 21769012.
      View in: PubMed   Mentions: 6     Fields:    
    77. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis. 2009 Apr; 197(4):225-31. Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, Rawson R, Methamphetamine Treatment Project Corporate Authors. PMID: 19363377; PMCID: PMC2749575.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    78. Hepatitis A and B infection among methamphetamine-dependent users. J Subst Abuse Treat. 2008 Oct; 35(3):351-2. Gonzales R, Marinelli-Casey P, Hillhouse M, Hunter J, Rawson RA, Mooney L, Ang A. PMID: 18640808.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    79. Identifying methamphetamine users at risk for major depressive disorder: findings from the methamphetamine treatment project at three-year follow-up. Am J Addict. 2008 Mar-Apr; 17(2):99-102. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, Methamphetamine Treatment Project. PMID: 18393051.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    80. Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat. 2008 Dec; 35(4):445-50. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, Methamphetamine Treatment Project Corporate Authors. PMID: 18294802.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    81. Risk factors for suicide attempts in methamphetamine-dependent patients. Am J Addict. 2008 Jan-Feb; 17(1):24-7. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, Methamphetamine Treatment Project. PMID: 18214719.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    82. Predatory behavior of Polistes dominulus wasps in response to cardenolides and glucosinolates in Pieris napi caterpillars. J Chem Ecol. 2007 Jun; 33(6):1177-85. Rayor LS, Mooney LJ, Renwick JA. PMID: 17453324.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    Larissa's Networks
    Concepts (226)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (17)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-9-g3adcefa5 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California